| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Cellular Biology |
From the Department of Pharmacology (S.C., R.S.), University of Bristol; and Institute of Membrane & Systems Biology (J.C.), University of Leeds, UK.
Correspondence to Rebecca Sitsapesan, University of Bristol, Department of Pharmacology, School of Medical Sciences, University Walk, Bristol BS8 1TD, UK. E-mail r.sitsapesan{at}bris.ac.uk
| Abstract |
|---|
|
|
|---|
Key Words: phosphorylation ryanodine receptor Ca2+ release excitationcontraction coupling
| Introduction |
|---|
|
|
|---|
In view of the controversy surrounding the molecular basis of heart failure, we have investigated the effects of PKA-dependent phosphorylation on the gating and conduction of RyR2 and related the changes in single-channel function to serine-2809 phosphorylation levels. This study has defined clear functional consequences of RyR2 phosphorylation and evaluated whether serine-2809 phosphorylation is a worthwhile marker for these functional states. We show that PKA-dependent phosphorylation of serine-2809 on RyR2 at levels up to and including 75% of maximum is associated with modest changes in Po with no apparent subconductance state gating. However, phosphorylation above this level causes marked increases in Po and current amplitude, although channels still do not gate in subconductance states. We suggest that maximum phosphorylation at serine-2809 is normally a short-lived event that occurs in response to adrenergic stimulation. If the substantial changes to channel behavior resulting from maximum phosphorylation at serine-2809 were to be maintained, it is likely that pathological changes to cellular Ca2+-handling mechanisms could occur.
| Materials and Methods |
|---|
|
|
|---|
Data Acquisition and Analysis
Channel recordings were displayed on an oscilloscope and recorded on digital audiotape (DAT). Current recordings were filtered at between 800 Hz and 1 kHz (3 dB) and digitized at 20 kHz using Pulse (HEKA Elektronik Dr Schulze GmbH, Lambrecht/Pfalz, Germany). Channel open probability (Po) was determined over 3 minutes of continuous recording, unless otherwise stated, using the method of 50% threshold analysis.11 Lifetime analysis was performed only when a single channel incorporated into the bilayer. Events <1 ms in duration were not fully resolved and were excluded from lifetime analysis. Individual lifetimes were fitted to a probability density function (pdf) by the method of maximum likelihood according to the equation equation
|
|
Where ln
I is the logarithm of the ith time constant and ai is the fraction of the total events represented by that component.12 Single-channel current amplitudes were measured from digitized data using manually control cursors and the single channel analysis software Windows EDR V2.4.9 (University of Strathclyde, UK).
Alteration of Phosphorylation State at Serine-2809 on RyR2
For alkaline phosphatase dephosphorylation of RyR2, cardiac SR vesicles were incubated with 1 U of alkaline phosphatase per µg protein for 30 minutes at 37°C in a solution containing 50 mmol/L HEPES, 16 mmol/L Tris, pH 7.2. For PP1 dephosphorylation of RyR2, cardiac SR vesicles were incubated with 0.1 U PP1 per microgram of protein for 10 minutes at 37°C in a solution containing 50 mmol/L HEPES, 16 mmol/L Tris, 1 mmol/L MnCl2, 50 mmol/L DTT, pH 7.2. For PKA phosphorylation of RyR2, cardiac SR vesicles were incubated with 0.5 U of the catalytic subunit of PKA per µg protein for 5 minutes at 37°C in a solution containing 50 mmol/L HEPES, 16 mmol/L Tris, 1 mmol/L ATP, 5 mmol/L MgCl2, 5 mmol/L NaF, pH 7.2. At the end of the relevant incubation time for PKA, ice-cold buffer containing 250 mmol/L HEPES, 80 mmol/L Tris, 5 mmol/L NaF, pH 7.2, was added to each sample. Samples were centrifuged at 9720g for 10 minutes at 4°C, the supernatant removed, and the samples resuspended in ice-cold buffer. Samples were centrifuged at 9720g for 10 minutes at 4°C and finally resuspended at the relevant protein concentration in the same buffer. Samples were then used for Western blotting.
Western Blotting
Heavy SR proteins were size fractionated by SDS-PAGE on a 6% polyacrylamide gel.13 Following separation, proteins were transferred to nitrocellulose membranes and nonspecific binding sites were blocked for 1.5 to 2 hours at room temperature using 5% dried milk and Tris-buffered saline (pH 7.4), 0.1% Tween 20. Membranes were probed over night at 4°C with primary antibodies specific for RyR phosphorylated (RYR2-PS2809) or dephosphorylated (RYR22809deP) at serine-2809.14 A secondary horseradish peroxidase linked anti-rabbit IgG (Amersham Biosciences, Buckinghamshire, UK) was used in combination with an enhanced chemiluminescent detection system (Pierce Biotechnology Inc, Rockford, Ill) to visualize the primary antibodies.
Determination of Phosphorylation State at Serine-2809 on RyR2
PKA treatment resulted in complete phosphorylation at serine-2809 as demonstrated by the increase in staining with the RYR2-PS2809 antibody and the absence of signal from the RYR22809deP antibody. RYR2-PS2809 staining of control and PKA-treated samples was quantified by densitometry and the control was expressed as a percentage of the PKA-treated samples. Alkaline phosphatase treatment resulted in complete dephosphorylation at serine-2809, as demonstrated by the increase in staining with RYR22809deP and the absence of RYR2-PS2809 signal. Comparing the RYR22809deP staining of a control sample with the AP-treated sample staining gives the percentage of dephosphorylated monomers in the sample. It is therefore possible to work out the basal level of phosphorylation. In all cases, control and treated samples were always quantified from the same Western blot. Densitometry was performed using Scion Image (Scion Corporation, Frederick, Md), and the level of staining did not saturate the measurement by the densitometry software in any blot quantified.
Statistics
All values given are mean±SEM. A probability value of 0.05 was taken as significant, as determined by Student t test.
Materials
Alkaline phosphatase was obtained from Roche Diagnostics GmbH (Mannheim, Germany). Protein phosphatase 1 (PP1) was obtained from New England Biolabs (Ipswich, Mass). The catalytic subunit of PKA was obtained from Sigma-Aldrich Company Ltd (Dorset, UK). Other chemicals were AnalaR or the best equivalent grade from BDH (Poole, UK) or Sigma-Aldrich Company Ltd (Dorset, UK). All solutions were made up in deionized water and those for use in bilayer experiments were filtered through a Millipore membrane filter (0.45-µm pore).
| Results |
|---|
|
|
|---|
|
|
Figure 3 illustrates the effects of further PKA-dependent phosphorylation of RyR2 to a level we believe equates to stoichiometric phosphorylation of serine-2809. We recorded a 3-minute control period in the presence of physiological levels of cytosolic ATP (10 mmol/L), free Mg2+ (0.5 mmol/L), and 10 µmol/L Ca2+ (Figure 3, left). Note that because of the stochastic nature of channel gating, the trace is not representative of Po but has been specifically chosen to include long open events to illustrate control full open-channel level. After 3 minutes of incubation with PKA on the cytosolic side of the channel, PKA was perfused away to rule out the possibility of any proteinprotein interactions between RyR2 and PKA. Channel activity was then recorded for a further 3 minutes (Figure 3, right). A large increase in Po and a small, but significant, increase in single-channel conductance were observed. The mean data are shown in the histograms in Figure 3B and 3C. Amplitude histograms shown in Figure 3D and 3E confirm that resolvable subconductance states were not observed. The increase in Po (from 0.126±0.066 to 0.673±0.164 [SEM]; n=6) was characterized by a marked change in the gating of the channel, in particular, a large increase in mean open times from 4.06±1.69 to 134±83.9 ms (SEM; n=4) was observed. The change in mean closed times from 30.00±10.01 ms in control to 10.73±6.58 ms after PKA incubation was small in comparison. Lifetime analysis (Figure 4) confirms that phosphorylation of the channel caused an increase in both the frequency and the duration of channel openings but that the increase in open lifetime duration was mainly responsible for the increased Po.
|
|
To support our assumption that the effects of PKA were manifest by protein phosphorylation, we incubated channels for 5 minutes with PKA in the absence of ATP and Mg2+. Under these conditions, PKA did not produce any changes in conductance or gating. In the presence of 50 µmol/L cytosolic Ca2+, Po was 0.141±0.054 before and 0.128±0.084 (SEM; n=5) after PKA incubation. Single-channel current amplitude was 4.53±0.043 pA before and 4.72±0.101 after PKA incubation. These results were confirmed by the use of the inhibitor of PKA, protein kinase inhibitor (PKI). PKI, on its own (in the presence of Mg2+ and ATP), had no effect (results not shown), but the peptide was able to completely abolish the effects of PKA (Po was 0.191±0.104 before and 0.261±0.145 after PKA incubation [SEM]; n=4).
We then wanted to investigate how dephosphorylation of RyR2 would affect the gating and conducting properties of the channel. We used the protein phosphatase PP1 for 2 reasons. Firstly, it has been shown to be associated with RyR2, and, secondly, it proved to be effective at dephosphorylating RyR2 when incubated with hSR for short periods of time (10 minutes) at room temperature. This then allowed us to perform the bilayer experiments with relatively short incubation periods. In contrast, alkaline phosphate could not completely dephosphorylate RyR2 under bilayer conditions, requiring incubation of hSR samples to 37°C and augmentation of its effect by denaturation of RyR2 in Laemmli sample buffer (data not shown). Western blot analysis shown in Figure 5A illustrates that the protein phosphatase PP1 can dephosphorylate RyR2 from the basal level of approximately 75% of maximum to a substantially dephosphorylated level below the detection limits of the RYR2-PS2809 antibody. PP1 could therefore be used to dephosphorylate RyR2 already incorporated into bilayers. We recorded RyR2 current fluctuations for 3 minutes (Figure 5B, top trace), incubated the cytosolic side of RyR2 with 5 U of PP1 for 10 minutes, and then recorded for a further 3 minutes after washing away the PP1 (Figure 5B, bottom trace). Dephosphorylation of the channel by PP1 (5 U) caused a small increase in Po (from 0.074±0.032 to 0.218±0.028 [SEM]; n=4; Figure 5C) but no change in current amplitude (Figure 5D). Again, amplitude histograms show no evidence of subconductance states (Figure 5E and 5F). Figure 6 illustrates the changes in open and closed lifetime distributions caused by dephosphorylating from approximately 75% of the maximum level at serine-2809 to a situation close to complete dephosphorylation at serine-2809. The figure demonstrates that the increase in Po results mainly from an increase in the frequency of channel opening. We then performed experiments where we doubled the PP1 levels in the cytosolic chamber to 10 U. The effects on gating and conductance were similar to the effects observed with 5 U of PP1 (mean Po was 0.059±0.017 before and 0.256±0.108 after) providing evidence that essentially maximum dephosphorylation had already taken place with 5 U of PP1.
|
|
| Discussion |
|---|
|
|
|---|
We also demonstrated that the coincidence of serine-2809 phosphorylation with changes in channel activity is not described by a simple relationship. Modest changes in channel function are observed at serine-2809 phosphorylation levels up to 75% of maximum, with dramatic changes in channel activity occurring beyond this level of phosphorylation. This nonlinear relationship underscores the need for careful definition of phosphorylation status in studies of RyR2 function and suggests that the term hyperphosphorylation should only be reserved for protein phosphorylated to stoichiometry, rather than its current usage in the literature.
The prevailing message of current literature is that phosphorylation of RyR2 on serine-2809 to 75% of maximum is a state of hyperphosphorylation and that this is seen only in pathological situations in which the hyperphosphorylation results in channel dysregulation sufficient to cause cardiac dysfunction.1 The present study reveals 2 central findings that do not support this hypothesis. Firstly, we have found that RyR2 exhibits a high level of basal phosphorylation at serine-2809, which is already 75% of maximum. A high level of phosphorylation at serine-2809 in control cardiac SR preparations is not uncommon and has been observed by several groups using protein derived from various species (rabbit, dog, mouse, human),4,5,7 although 1 group has reported low levels.1 Secondly, channel activity at this 75% phosphorylation level was low and displayed no sign of dysregulation (subconductance states) as has been reported by 1 group.1 The functional characterization of channels phosphorylated to 75% of maximum (at serine-2809) was measured comprehensively. Thirty channels displayed a low Po (0.059±0.01 [SEM]; n=30) with individual values ranging from 0.002 to 0.1943. Furthermore, much of our previous work has been conducted on control sheep cardiac RyR2, and thus one can assume that these channels were also phosphorylated to 75% of maximum at serine-2809, as the procedures for isolation of hSR and reconstitution of RyR2 into bilayers were identical to the present study. The behavior of channels in these previous studies (for example, Sitsapesan and Williams,15 Sitsapesan et al,16 and Chan et al17) is essentially identical to the behavior described for control channels in the present study, which increases the number of observations inconsistent with the previous hyperphosphorylation model of cardiac dysfunction.1
A large enhancement in channel activity was observed following additional phosphorylation by PKA. This was characterized by an increase in Po and an increase in the single-channel conductance of RyR2 but was again without the appearance of subconductance states. In parallel studies, the phosphorylation status of serine-2809 was assessed and was shown to be stoichiometric, suggesting that the enhanced activity of the channel measured in the bilayer, requires full (stoichiometric) phosphorylation at serine-2809. These clear changes to RyR2 channel function have not previously been reported, and they differ significantly from the original description of hyperphosphorylated channels.1 In the original study, hyperphosphorylation of serine-2809 on RyR2 (75% of maximum) was associated with a modest increase in Po (0.1 to 0.35), no change in mean open time, but the appearance of frequent openings to long-lived subconductance states.1 RyR2 subconductance states and other forms of dysregulation have been observed following damage to the channel and on solubilization from the SR. Jiang et al5 observed subconductance states following limited proteolysis of RyR2, whereas Laver et al16 observed altered Ca2+ regulation of the channel following solubilization of SR with the detergent CHAPS. The present study has minimized hostile treatment of RyR2, avoiding all detergents and using a comprehensive cocktail of protease inhibitors in the isolation of hSR. It is conceivable that this might underlie the difference between the present observations and those of Marks and colleagues,1 who used, in some studies, RyR2 that was solubilized and immunoprecipitated before functional interrogation.
Our final major finding is that a reduced level of phosphorylation at serine-2809 to below the 75% level is associated with a small increase in Po, although lifetime analysis demonstrates that the mechanisms underlying this change in gating are very different to that observed when phosphorylating the channel to stoichiometry at serine-2809. The modest enhancement in Po results from abbreviation of the closed lifetime durations without change to open lifetime durations. The results agree with those of Terentyev et al, who also found that phosphatase treatment increased RyR2 Po.18 The use of PP1 to dephosphorylate RyR2 is not, of course, specific for serine-2809; PP1 will dephosphorylate at other sites including other PKA sites and CaMKII sites. Therefore, the rise in Po that we observed when dephosphorylating from approximately 75% of maximum to approximately zero levels at serine-2809 either could have been attributable solely to dephosphorylation at serine-2809 or could have also included a component resulting from dephosphorylation at another site. As there is controversy over the number of PKA phosphorylation sites, the number of CaMKII sites and the functional effects of changing phosphorylation levels at these sites, at this point, no simple experiment can be performed to address this issue. From the evidence in the literature, however, we can reflect on the most likely situation. A second PKA phosphorylation site on RyR has been reported, serine-2030,4 although this has recently been questioned.19 This phosphorylation site is fully dephosphorylated in the absence of a ß agonist,4,20 and, thus, it is likely to be dephosphorylated in our hSR preparation. The evidence suggests, therefore, that the effects we observe with PP1 are unlikely to be caused by dephosphorylation of serine-2030.
Could the increase in Po that we observe after incubation with PP1 partially result from dephosphorylation of a specific CaMKII site? A large number of CaMKII phosphorylation sites have been suggested on RyR2,14 of which only serine-2815 has been identified to date.21 In advance of the identification of these sites, and knowledge of their phosphorylation status before and after PP1 treatment, there is little value in speculating what role they perform in the dephosphorylation-dependent enhancement of RyR2 activity. Instead, we can conclude that the phosphorylation status of serine-2809 at the 3 levels examined coincides with 3 distinct functional states of RyR2. In that capacity, it can be used as a marker of the functional state of the RyR2 protein, although a careful quantitative assessment of the stoichiometry of serine-2809 phosphorylation is required to interpret this accessible marker of channel activity.
It is interesting to note that in the analysis of 30 separate channels from a population phosphorylated on serine-2809 to 75% of maximum, no example of a channel exhibiting the "fully phosphorylated" characteristics (high Po, long open lifetimes, increased single-channel conductance) was observed. If we assume that serine-2809 phosphorylation is the sole contributor to enhanced channel activity, then one might have expected to observe a fully active channel from this population in a random sample of 30, if phosphorylation status were normally distributed within the population. Our failure to observe a fully active channel in the control population would suggest that phosphorylation is not normally distributed and that the incidence of stoichiometric phosphorylation in this population is low. That would suggest a negative cooperativity in the process of phosphorylation of this site. Alternatively, serine-2809 phosphorylation may not be the sole trigger for enhanced RyR2 activity. One additional PKA phosphorylation site has been described within RyR2 (serine-20304), and this site would be expected to become phosphorylated in response to PKA addition. However, serine-2030 phosphorylation is not associated with increased Po, as judged by ryanodine binding,4 and thus either a combination of serine-2809 and serine-2030 phosphorylation is required or a dramatic activation of the channel accompanies phosphorylation of the final subunit in a tetramer on serine-2809.
The physiological significance of the present findings are considerable. The RyR, as isolated from the cell, has a phosphorylation status that positions the channel at a low point in a complicated activity landscape. Activity of the channel can be raised either by increasing the phosphorylation state of the channel or conversely by decreasing the phosphorylation state of the channel. These changes in activity are not symmetrical (in terms of magnitude) or equivalent (in terms of molecular basis) but, rather, accomplish a substantial increase in channel activity with modest increases in serine-2809 phosphorylation or conversely a modest increase in channel activity with substantial reductions in serine-2809 phosphorylation. This might allow for rapid and dramatic changes in function on PKA activation (a switch from 3 to 4 subunits phosphorylated at serine-2809) but also permits influence on RyR2 function from other pathways able to augment phosphatase activity and effect a more modest enhancement of RyR2 function.
Physiologically, stoichiometric phosphorylation at serine-2809 may be a very transient event that occurs in response to adrenergic stimulation. If stoichiometric phosphorylation at serine-2809 were to become less transitory, this would be expected to have serious consequences on the intracellular Ca2+ handling of cardiac cells because the changes to channel gating and conductance are so extreme. Such a situation might exist in heart failure. Circulating catecholamine levels can be elevated in heart failure patients22 and Marx et al1 have provided evidence indicating that the levels of phosphatases associated with RyR2 are lowered in heart failure. Hence, there is potential for dysregulation of the balance between kinase and phosphatase activity at RyR2 enabling a more readily achievable stoichiometric phosphorylation at serine-2809. Further work is required to determine whether stoichiometric phosphorylation of serine-2809 on RyR2 can occur for prolonged periods in heart disease.
| Acknowledgments |
|---|
This work was supported by the British Heart Foundation.
Disclosures
J.C. operates a company that distributes antibodies commercially. These antibodies were used in the present study.
| Footnotes |
|---|
| References |
|---|
|
|
|---|
2. Reiken SR, Gaburjakova M, Guatimosim S, Gomez AM, DArmiento J, Burkhoff D, Wang J, Vassort G, Lederer J, Marks AR. PKA phosphorylation of the cardiac calcium release channel (ryanodine receptor) in normal and failing hearts: role of phosphatases and response to isoproterenol. J Biol Chem. 2002; 278: 444453.[CrossRef][Medline] [Order article via Infotrieve]
3. Xiao B, Sutherland C, Walsh MP, Chen SR. Protein kinase A phosphorylation at serine-2808 of the cardiac Ca2+-release channel (ryanodine receptor) does not dissociate 12.6-kDa FK506-binding protein (FKBP12.6). Circ Res. 2004; 94: 487495.
4. Xiao B, Jiang MT, Zhao M, Yang D, Sutherland C, Lai FA, Walsh MP, Warltier DC, Cheng H, Chen SR. Characterization of a novel PKA phosphorylation site, serine-2030, reveals no PKA hyperphosphorylation of the cardiac ryanodine receptor in canine heart failure. Circ Res. 2005; 96: 847855.
5. Jiang MT, Lokuta AJ, Farrell EF, Wolff MR, Haworth RA, Valdivia HH. Abnormal Ca2+ release, but normal ryanodine receptors, in canine and human heart failure. Circ Res. 2002; 91: 10151022.
6. Li Y, Kranias EG, Mignery GA, Bers DM. Protein kinase A phosphorylation of the ryanodine receptor does not affect calcium sparks in mouse ventricular myocytes. Circ Res. 2002; 90: 309316.
7. Stange M, Xu l, Balshaw D, Yamaguchi N, Meissner G. Characterization of recombinant skeletal muscle (Ser-2843) and cardiac muscle (Ser-2809) ryanodine receptor phosphorylation mutants. J Biol Chem. 2003; 278: 5169351702.
8. Valdivia HH, Kaplan JH, Ellis-Davies GCR, Lederer WJ. Rapid adaptation of cardiac ryanodine receptors: modulation by Mg2+ and phosphorylation. Science. 1995; 267: 19972000.
9. Marx SO, Gaburjakova J, Henrikson C, Ondrias K, Marks AR. Coupled gating between cardiac calcium release channels (ryanodine receptors). Circ Res. 2001; 88: 11511158.
10. Sitsapesan R, Montgomery RAP, MacLeod KT, Williams AJ. Sheep cardiac sarcoplasmic reticulum calcium release channels: modification of conductance and gating by temperature. J Physiol. 1991; 434: 469488.
11. Colquhoun D, Sigworth FJ. Fitting and statistical analysis of single-channel recording. In: Sakmann B, Neher E, eds. Single-Channel Recording. New York and London: Plenum; 1983.
12. Sigworth FJ, Sine SM. Data transformations for improved display and fitting of single-channel dwell time histograms. Biophys J. 1987; 52: 10471054.[Medline] [Order article via Infotrieve]
13. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 1970; 227: 680685.[CrossRef][Medline] [Order article via Infotrieve]
14. Rodriguez P, Bhogal MS, Colyer J. Stoichiometric phosphorylation of cardiac ryanodine receptor on serine 2809 by calmodulin-dependent kinase II and protein kinase A. J Biol Chem. 2003; 278: 3859338600.
15. Sitsapesan R, Williams AJ. Mechanisms of caffeine activation of single calcium-release channels of sheep cardiac sarcoplasmic reticulum. J Physiol. 1990; 423: 425439.
16. Sitsapesan R, McGarry SJ, Williams AJ. Cyclic ADP-ribose competes with ATP for the adenine nucleotide binding site on the cardiac ryanodine receptor Ca2+-release channel. Circ Res. 1994; 75: 596600.
17. Chan WM, Welch W, Sitsapesan R. Structural factors that determine the ability of adenosine and related compounds to activate the cardiac ryanodine receptor. Br J Pharmacol. 2000; 130: 16181626.[CrossRef][Medline] [Order article via Infotrieve]
18. Terentyev D, Viatchenko-Karpinski S, Gyorke I, Terentyeva R, Gyorke S. Protein phosphatases decrease sarcoplasmic reticulum calcium content by stimulating calcium release in cardiac myocytes. J Physiol. 2003; 552: 109118.
19. Wehrens XH, Lehnart SE, Reiken S, Vest JA, Wronska A, Marks AR. Ryanodine receptor/calcium release channel PKA phosphorylation: a critical mediator of heart failure progression. Proc Natl Acad Sci U S A. 2006; 103: 511518.
20. Xiao B, Zhong G, Obayashi M, Yang D, Chen K, Walsh MP, Shimoni Y, Cheng H, Ter Keurs H, Chen SR. Serine-2030, but not Serine-2808, is the major phosphorylation site in cardiac ryanodine receptor responding to protein kinase A activation upon beta-adrenergic stimulation in normal and failing hearts. Biochem J. 2006.
21. Wehrens XH, Lehnart SE, Reiken SR, Marks AR. Ca2+/calmodulin-dependent protein kinase II phosphorylation regulates the cardiac ryanodine receptor. Circ Res. 2004; 94: e61e70.
22. Cohn JN, Levine TB, Olivari MT, Garberg V, Lura D, Francis GS, Simon AB, Rector T. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med. 1984; 311: 819823.[Abstract]
This article has been cited by other articles:
![]() |
P. Zhou, Y.-T. Zhao, Y.-B. Guo, S.-M. Xu, S.-H. Bai, E. G. Lakatta, H. Cheng, X.-M. Hao, and S.-Q. Wang {beta}-Adrenergic signaling accelerates and synchronizes cardiac ryanodine receptor response to a single L-type Ca2+ channel PNAS, October 20, 2009; 106(42): 18028 - 18033. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. M. Blayney, J.-L. Jones, J. Griffiths, and F. A. Lai A mechanism of ryanodine receptor modulation by FKBP12/12.6, protein kinase A, and K201 Cardiovasc Res, September 2, 2009; (2009) cvp273v2. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. L. Hamilton and I. I. Serysheva Ryanodine Receptor Structure: Progress and Challenges J. Biol. Chem., February 13, 2009; 284(7): 4047 - 4051. [Full Text] [PDF] |
||||
![]() |
Y.-H. Yeh, R. Wakili, X.-Y. Qi, D. Chartier, P. Boknik, S. Kaab, U. Ravens, P. Coutu, D. Dobrev, and S. Nattel Calcium-Handling Abnormalities Underlying Atrial Arrhythmogenesis and Contractile Dysfunction in Dogs With Congestive Heart Failure Circ Arrhythm Electrophysiol, June 1, 2008; 1(2): 93 - 102. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Zhu, A. A. Gach, G. Liu, X. Xu, C. C. Lim, J. X. Zhang, L. Mao, K. Chuprun, W. J. Koch, R. Liao, et al. Enhanced calcium cycling and contractile function in transgenic hearts expressing constitutively active G{alpha}o* protein Am J Physiol Heart Circ Physiol, March 1, 2008; 294(3): H1335 - H1347. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Ikeda, M. Hoshijima, and K. R. Chien Toward Biologically Targeted Therapy of Calcium Cycling Defects in Heart Failure Physiology, February 1, 2008; 23(1): 6 - 16. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. H. George Sarcoplasmic reticulum Ca2+ leak in heart failure: mere observation or functional relevance? Cardiovasc Res, January 15, 2008; 77(2): 302 - 314. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. F. James Inhibition of SR Ca2+ uptake: A novel action of the RyR2-FKBP12.6 antagonist K201 Cardiovasc Res, November 1, 2007; 76(2): 199 - 201. [Full Text] [PDF] |
||||
![]() |
B. Xiao, X. Tian, W. Xie, P. P. Jones, S. Cai, X. Wang, D. Jiang, H. Kong, L. Zhang, K. Chen, et al. Functional Consequence of Protein Kinase A-dependent Phosphorylation of the Cardiac Ryanodine Receptor: SENSITIZATION OF STORE OVERLOAD-INDUCED Ca2+ RELEASE J. Biol. Chem., October 12, 2007; 282(41): 30256 - 30264. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. A. Benkusky, C. S. Weber, J. A. Scherman, E. F. Farrell, T. A. Hacker, M. C. John, P. A. Powers, and H. H. Valdivia Intact {beta}-Adrenergic Response and Unmodified Progression Toward Heart Failure in Mice With Genetic Ablation of a Major Protein Kinase A Phosphorylation Site in the Cardiac Ryanodine Receptor Circ. Res., October 12, 2007; 101(8): 819 - 829. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Seidler, G. Hasenfuss, and L. S. Maier Targeting Altered Calcium Physiology in the Heart: Translational Approaches to Excitation, Contraction, and Transcription Physiology, October 1, 2007; 22(5): 328 - 334. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Pereira, M. Metrich, M. Fernandez-Velasco, A. Lucas, J. Leroy, R. Perrier, E. Morel, R. Fischmeister, S. Richard, J.-P. Benitah, et al. The cAMP binding protein Epac modulates Ca2+ sparks by a Ca2+/calmodulin kinase signalling pathway in rat cardiac myocytes J. Physiol., September 1, 2007; 583(2): 685 - 694. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Kockskamper and B. Pieske Phosphorylation of the Cardiac Ryanodine Receptor by Ca2+/Calmodulin-Dependent Protein Kinase II: The Dominating Twin of Protein Kinase A? Circ. Res., August 18, 2006; 99(4): 333 - 335. [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Circulation Research Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2006 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |